| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c56417b20d0561e41e7a4e886b502cbc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
| filingDate |
2000-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71aa43ccfd7d24f3e8e0fcc772276595 |
| publicationDate |
2003-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2350195-C |
| titleOfInvention |
Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
| abstract |
Provided herein is a novel enterically-coated pyridoxine HCl and doxylamine succinate rapid onset formulation for treating nausea and vomiting comprising a disintegrating agent such that the following dissolution profiles are satisfied when measur ed in 1000 ml phosphate buffer at pH 6.8 and 37.degree.C in a type 2 dissolution apparatus at 100 rpm: (a) at least about 40% of the total pyridoxine HCl and doxylamine succinate is dissolved after 30 minutes of measurement; (b) at least about 70% of the total pyridoxine HCl and doxylamine succinate is dissolved after 60 minutes of measurement; (c) at least about 80% of the total pyridoxine HCl and doxylamine succinate is dissolved after 90 minutes of measurement; (d) at about 90% of the total pyridoxine HCl and doxylamine succinate is dissolved after 120 minutes of measurement. Preferably the formulation will contain a core coated with at least one enteric coating, the core comprising pyridoxine HCl, doxylamine succinate and the following non- active excipients: a filler or binder, a disintegrating agent, a lubricant, a silic a flow conditioner and a stabilizing agent. |
| priorityDate |
2000-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |